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Abstract: Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for 
cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such 
patients is elevated. Recent studies have shown that regular use of cardiovascular medications, 
such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing 
long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system plays 
an important role in the pathogenesis and progression of atherosclerosis, and ACE-inhibitors 
(ACE-I) seem to have vasculoprotective and antiproliferative effects as well as a direct anti-
atherogenic effect. ACE-I also promote the degradation of bradykinin and the release of nitric 
oxide, a potent vasodilator; further, thay have shown important implications for vascular oxida-
tive stress. Other studies have suggested that ACE-I may also improve endothelial dysfunction. 
ACE-I are useful for reducing the risk of cardiovascular events in clinical and subclinical PAD. 
Particularly, one agent of the class (ie, ramipril) has shown in many studies to able to signiﬁ  cantly 
reduce cardiovascular morbidity and mortality in patients with PAD.
Keywords: atherosclerosis, peripheral arterial disease, endothelial dysfunction, 
ACE-inhibitors
Introduction
Peripheral arterial disease (PAD) of the lower limbs is the third most important site of 
atherosclerotic disease alongside coronary heart disease (CHD) and cerebrovascular 
disease (CVD) (Novo 1995). This clinical condition has often been neglected in the 
past but, in recent years, PAD has received growing attention as an important cause 
of disability and of cardiovascular morbidity and mortality (Novo and Coppola 
2002; Novo 1995). Subjects with PAD represent a category of patients at a very high 
cardiovascular risk of fatal and non-fatal cerebrovascular and cardiovascular events; 
therefore, they need to be treated not only for local problems derived from arteriopathy 
(intermittent claudication, rest pain and/or ulcers) but, above all, for preventing vas-
cular events (Clement et al 2000; Gibbons et al 2003; Bhatt et al 2006; Antman et al 
2004). Simple non-invasive tests such as measurement of Ankle/Brachial pressure 
Index (ABI), the so-called Index of Winsor, and ankle and toe Doppler pressures 
represent easy and useful methodologies in clinical practice; in fact, such tests can be 
performed in only a few minutes and can provide sufﬁ  cient information to conﬁ  rm 
the diagnosis of PAD and to document the severity of limb ischemia (Dormandy 
and Rutherford 2000; Milio et al 2004). The echographic examination of carotid and 
peripheral atherosclerotic lesions may be useful in patients with PAD for identifying 
subjects at higher risk for cerebrovascular and cardiovascular events, and their early 
identiﬁ  cation may favor more aggressive approaches of pharmacological treatment 
in order to avoid future events (Romano et al 2006). Recently, a number of studies 
have suggested that ramipril, an angiotensin-converting enzyme inhibitor (ACE-I), 
and statins, together with antiplatelet drugs, may reduce cardiovascular morbidity Vascular Health and Risk Management 2008:4(6) 1180
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and mortality in PAD (Novo and Evola 2003; Coppola and 
Novo 2007).
ACE-I were developed as therapeutic agents for essential 
arterial hypertension. Since the initial application of these 
drugs, several additional clinical indications have been 
identiﬁ  ed and approved (Brown and Vaughan 1998), such as 
reduction in mortality and hospitalizations for heart failure in 
patients with moderate left ventricular dysfunction, with and 
without signs or symptoms of congestive heart failure; beneﬁ  ts 
in patients with ischemic and non-ischemic cardiomyopathies 
and with or without recent myocardial infarction (SOLVD 
Investigators 1991; Pfeffer et al 1992); and reductions in left 
ventricular remodeling (Pfeffer et al 1988; Sharpe et al 1991). 
Recently, the role of the rennin-angiotensin-aldosterone 
system (RAAS) has been described in the pathogenesis and 
progression of atherosclerosis (Lonn et al 1994). Peripheral 
artery disease (PAD) is related to atherosclerotic stenosis and 
inappropriate dilatation or abnormal constriction of arteries 
and microcirculation (Meredith et al 1993; Hasdai et al 1997). 
Endothelial dysfunction represents one of the mechanisms 
involved in the disturbance of artery vasomotion. The central 
role of endothelium in vascular tone regulation is due to its 
ability to release both vasodilating and vasoconstricting sub-
stances. In animal models, ACE-I can retard the development 
of atherosclerosis, and these antiatherogenic properties 
can be related to the inhibition of angiotensin-II (Ang II) 
formation and to the inhibition of bradykinin degradation, 
which promotes vasodilatation by stimulating the production 
of arachidonic acid metabolites and nitric oxide (NO) in 
vascular endothelium. In summary, the ACE system regulates 
the balance between the vasodilatory properties of bradykinin 
and the vasoconstrictive properties of Ang II. ACE-I alter 
this balance by decreasing the formation of Ang II and the 
degradation of bradykinin (Figure 1): the bradykinin is 
potentiated and NO is released to a greater extent, resulting 
in decreased migration and proliferation of vascular smooth 
muscle cells, decreased accumulation and activation of 
inﬂ  ammatory cells, decreased oxidative stress, and improved 
endothelial function.
Vasculoprotective effects
of ACE-inhibitors
The vascular protective effects of ACE-I may be summarized 
as follows (Table 1).
Antiproliferative effects
ACE-I exhibit antiproliferative effects (reduction of vas-
cular and cardiac hypertrophy and extracellular matrix 
proliferation) and reduce ventricular remodeling after 
myocardial infarction (Paul and Ganten 1992; Schiffrin 
and Deng 1995). In the hypertrophied heart ACE-I reduce 
cardiac hypertrophy and improve diastolic function. ACE-I 
also prevent apoptosis of cardiac myocytes in pressure-
overloaded hearts.
In contrast to these antiproliferative and antimigratory 
effects, an enhancement of endothelial cell migration has 
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Figure 1 Renin-angiotensin system and kallikrein-kinin system. Angiotensin-converting enzymes regulate the balance between angiotensin-II (Ang II) and bradykinin.   Adapted 
from Brown and Vaughan (1998).Vascular Health and Risk Management 2008:4(6) 1181
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been demonstrated with ACE-I with reduced Ang II that 
may contribute to improved endothelial function and might 
therefore exert an antiatherosclerotic action.
Effects on the ﬁ  brinolytic balance
ACE-I also modulate the vascular ﬁ  brinolytic balance by 
decreasing Ang II, a potent activator of plasminogen activator 
inhibitor type 1 (PAI-1) synthesis, and by increasing levels 
of bradykinin, a potent activator for tissue plasminogen 
(Vaughan 1997). ACE-I lower plasminogen activator 
inhibitor type 1 (PAI-1) concentrations. PAI-1 represent 
the most important physiological inhibitor of tissue-type 
plasminogen activator (TPA) in plasma and elevated levels 
have been implicated in the pathogenesis of thromboembolic 
disease (Ridker 1992). It has been demonstrated that human 
platelets have Ang II receptors. The action of ACE-I on 
platelets could be related to Ang II blockade. Platelet aggre-
gation may also be suppressed through increased prostacyclin 
induced by elevated bradykinin levels.
Direct “antiatherogenic” effect
Vascular and cardioprotective properties of ACE-I largely 
result from their effects in inhibiting Ang II forma-
tion. Generation of Ang II is regulated by a circulating 
RAAS and a tissue angiotensin system, both of which 
are upregulated in cardiovascular diseases (Dzau and Re 
1994). Increased expression of tissue ACE has been found 
in the vasculature of subjects with hypertension and in the 
microvasculature throughout an atherosclerotic plaque, 
suggesting that the accumulation of ACE in the plaque 
contributes to increased local production of Ang II (Gibbons 
1995; Diet et al 1996). ACE inhibition modiﬁ  es the struc-
ture of the arterial wall and of vulnerable plaque, effects 
that might lead plaques to be less vulnerable to rupture. 
A direct “antiatherogenic” action of these drugs has been 
shown in several animal models of atherosclerosis related 
to cholesterol-mediated endothelial injury and in models 
of accelerated atherosclerosis after mechanical endothelial 
damage (balloon endothelial injury).
Chobanian et al (1990) studied the effects of captopril 
in the normotensive Watanabe Heritable Hyperlipidemic 
(WHHL) rabbit, an experimental model in which 
other blood-pressure-lowering drugs such as propranolol, 
nifedipine and verapamil failed to inhibit the development of 
atherosclerotic lesions. It appears, therefore, that in addition 
to a reduction in the anatomic extent of atherosclerotic 
lesions, captopril had potentially stabilizing effects on the 
atherosclerotic lesions, which may be associated with less 
propensity to rupture. Rolland et al (1993) demonstrated a 
reduction in the atherosclerotic lesion size, a decrease in 
the lipid-laden macrophages and less fragmentation of the 
arterial elastic tissue in the Pitman-Moore minipig treated 
with the ACE-I perindopril and receiving a high-fat diet. The 
atherosclerotic lesions that developed in perindopril-treated 
animals appeared less prone to rupture and had improved 
viscoelastic properties, favoring improved arterial ﬂ  ow. 
Although these ﬁ  ndings suggest potential beneﬁ  ts for the use 
of ACE-I in ischemic cardiovascular diseases beyond their 
hemodynamic effects, we need to view them with caution. 
The atherosclerotic plaques generated in animal models 
receiving high-cholesterol or high-fat diets are likely to 
differ from those observed in human atherosclerosis, so that 
the clinical impact of agents able to stabilize atherosclerotic 
lesions remains unclear.
Endothelial dysfunction
and atherosclerosis
The endothelium is a common target of all risk factors, and 
fuctional impairment of the vascular endothelium in response 
to injury occurs long before the development of atherosclerotic 
changes in arteries. Impaired endothelium-dependent 
vasodilation is an adverse prognostic parameter in patients 
with risk factors such as hypertension, diabetes, smoking, 
hypercholesterolemia and atherosclerotic vascular disease.
In patients with coronary heart disease (CHD), 
endothelial dysfunction predicts long-term atherosclerotic 
disease progression and cardiovascular event rates 
(Schächinger et al 2000).
A number of processes characterize endothelial 
dysfunction, enhanced vasoconstrictor responses, adhesion 
of platelets and monocytes, and proliferation and migration 
of vascular smooth muscle cells.
Table 1 Vasculoprotective effects of angiotensin-converting enzyme 
inhibitors (adapted from Lonn et al 1994)
Vasculoprotective effects
Direct antiatherogenic effect*
Antiproliferative and antimigratory effects on smooth muscle cells, 
neutrophils and mononuclear cells
Improvement and/or restoration of endothelial function
Protection from plaque rupture*
Antiplatelet effects
Enhancement of endogenous ﬁ  brinolysis*
Antihypertensive effects
Improvement in arterial compliance and tone
*Not demonstrated conclusively in humans.Vascular Health and Risk Management 2008:4(6) 1182
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ACE-I have been shown to improve or restore 
endothelial function in different animal models (Pepine 
1998; Enseleit et al 2003) and in humans. The Trial on 
Reversing Endothelial Dysfunction (TREND) showed 
convincing evidence for an effect of ACE inhibition on 
the endothelium-dependent vasodilation in subjects with 
coronary heart disease (Mancini et al 1996). After 6 months 
of quinapril treatment, the initial vasoconstrictor response 
to intracoronary infusion of acetylcholine was reduced and 
the vasodilator response was restored. Only the quinapril 
group showed signiﬁ  cant net improvement in response to 
incremental concentrations of acetylcholine (p = 0.002).
Galatius et al (1999) investigated the effect of 12 weeks 
of treatment with the ACE-I fosinopril on peripheral micro-
vascular function in a double-blind, placebo-controlled study 
of 12 patients treated with fosinopril and 10 patients treated 
with placebo. All had moderate congestive heart failure 
(CHF). Skeletal muscle vascular resistance and skin minimal 
vascular resistance were reduced in the fosinopril group 
(p   0.05 for both) while no changes were reported in the 
placebo group. These ﬁ  ndings suggest that long-term ACE-I 
treatment with fosinopril in patients with CHF improves the 
hemodynamic status as far as the peripheral microvascular 
level in both the relaxed and non-relaxed microcirculation 
of the lower legs. Such an effect appears to be mediated 
primarily by bradykinin accumulation.
Bradykinin is a peptide that stimulates the synthesis 
and/or activity of NO by binding to bradykinin receptors on 
the surface of endothelial cells. Accumulation of bradykinin 
via inhibition of ACE may increase NO synthesis or 
activity, resulting in improved vasodilative response. NO is 
synthesized in endothelial cells by a constitutively expressed 
enzyme, called endothelial NO synthase (eNOS ), or its 
inducible isoform, inducible NO synthase (iNOS ) (Hermann 
and Luscher 2006). NO is released from endothelial cells 
mainly in response to shear stress produced by blood ﬂ  ow 
or pharmacological stimulants such as acetylcholine. After 
diffusion from endothelial to vascular smooth muscle cells, 
NO increases intracellular cyclic guanosine-monophosphate 
(cGMP) concentrations leading to relaxation of the smooth 
muscle cells. Bradykinin also stimulates the endothelium 
to release prostacyclin (PGI-2) that is derived from the 
metabolism of arachidonic acid (Figure 2). PGI-2 relaxes 
most blood vessels by activating adenylyl cyclase and 
increasing cyclic adenosine monophosphate (cAMP) levels. 
PGI-2 is considered to be the main prostanoid synthesized 
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Figure 2 Endothelium-derived vasoactive substances. Various blood- and platelet-derived substances can activate speciﬁ  c receptors (open circles) on the endothelial membrane 
to release relaxing factors such as nitric oxide (NO), prostacyclin (PGI2), and an endothelium-derived hyperpolarizing factor (EDHF). Furthermore, contracting factors are 
released, such as endothelin-1 (ET-1) and angiotensin (Ang).   Adapted from Enseleit et al (2003).
Abbreviations: ACE, angiotensin-converting enzyme; NEP, neutral endopeptidase; Thr, thrombin; bET-l, big-endothelin-1; Bk, bradykinin; TX, thromboxane; O2, superoxide.Vascular Health and Risk Management 2008:4(6) 1183
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by vascular endothelium, while thromboxane A2 (TX-A2) 
is the main prostanoid produced by platelets.
Therefore, bradykinin may play a central role in 
preventing the development of proliferative atherosclerotic 
lesions in response to vascular injury (Cannon 1998).
ACE-inhibitors and oxidative stress
Increasing evidence suggests that ACE-I may have important 
implications for vascular oxidative stress (Münzel and 
Keaney 2001). Ang II stimulates the NADH/NAD(P)H 
(nicotinamide adenine dinucleotide/nicotinamide adenine 
dinucleotide phosphate) oxidases of endothelial and smooth 
muscle cells, resulting in increased generation of superoxide 
anions. The latter are able to degrade NO, with signiﬁ  cant 
implications for atherosclerosis development and progression. 
Superoxide combines with NO in a diffusion limited 
reaction that is faster than the dismutation of superoxide 
by the superoxide dismutase (which produces H2O2). This 
reaction produces peroxynitrite, a compound that reduces NO 
bioactivity and also promotes lipid and protein oxidation in 
atherosclerotic lesions, which decreases the bioavailability 
of endothelium-derived NO (Cannon 1998). In addition, the 
ACE-I limits the stimulation of vascular NAD(P)H oxidase, 
thereby preventing the increased superoxide ﬂ  ux associated 
with activation of the RAAS. This should produce a number of 
important downstream effects that beneﬁ  t the vasculature.
Because NO is known to inhibit the activity of NAD(P)H 
oxidase, another predictable effect of ACE-I would be to 
reduce the ambient levels of superoxide in the vascular wall 
(Lee et al 2000). ACE inhibition should also inhibit lipid 
peroxidation through reduced formation of peroxynitrite. Since 
superoxide is the principal source of H2O2, an agent typically 
associated with lipid and protein oxidation and necrosis or 
apoptosis in a number of cell types, ACE-I should limit smooth 
muscle proliferation. The relationship between ACE action and 
vascular oxidative stress is summarized in Figure 3.
Impact of ACE inhibition in PAD
Only a few studies have directly evaluated the potential 
role of ACE-I in PAD. Peripheral arterial disease remains 
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Figure 3 Scheme for relation between angiotensin-converting enzyme (ACE) action and vascular oxidative stress.   ACE inhibitors both stimulate NO production and prevent 
formation of O2
–, H2O2, and NO/C   2∼ reaction product peroxynitrite (ONOO–), thereby abrogating a number of downstream effects. In contrast, radical scavenging antioxidant 
vitamin E is active only against certain components of oxidative stress, leaving other consequences of NAD(P)H oxidase activity untouched.   Adapted from Münzel et al (2001).Vascular Health and Risk Management 2008:4(6) 1184
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an underdiagnosed disease in primary care and patients are 
not treated as aggressively such as those with other ischemic 
forms of atherosclerotic disease (McDermott et al 2001; 
Belch et al 2003). Cardiovascular events are still the 
major cause of morbidity and mortality in patients with 
PAD; therefore the potential benefit of an aggressive 
anti-atherosclerotic therapy still remains ill deﬁ  ned.
Higashi et al (2000) conducted a large multicenter study 
in 296 patients with essential arterial hypertension, including 
46 untreated subjects and 47 normotensive subjects. They 
compared calcium antagonists, beta-blockers, diuretics and 
ACE-I, evaluating the effects of these antihypertensive 
drugs on NO and prostaglandin release. After 24 weeks 
of treatment the reactive hyperemia was impaired in 
hypertensive patients compared with normotensive subjects 
(p   0.01). Reactive hyperemia was greater in hypertensive 
patients treated with ACE-I than in those treated with 
calcium antagonists (p   0.01), beta-blockers (p   0.01), 
diuretic agents (p   0.05) and untreated hypertensive 
patients (p   0.01). The increase in FBF (forearm blood ﬂ  ow) 
after administration of sublingual nitroglycerin (NTG) was 
similar in all groups. The maximal FBF response from reac-
tive hyperemia was signiﬁ  cantly greater in the ACE-I treated 
group than in the calcium antagonist, beta-blocker or diuretic 
agent groups or in untreated hypertensive subjects (p   0.05), 
but was similar among the last four groups. In this study all 
drugs were equally effective in reducing blood pressure, but 
only ACE-I improved endothelial dysfunction.
Ostergren et al (2004) evaluated the measurement of 
ABI as a predictor of cardiovascular events and the effect of 
ramipril treatment on prognosis in patients with symptomatic 
PAD in relation to those with different ABI but without 
symptomatic PAD. Clinical events in patients randomized 
to ramipril and placebo respectively for primary outcome 
(cardiovascular mortality, myocardial infarction, stroke) 
was 20.1% for ramipril and 25.8% for placebo, in clinical 
PAD, and 13.6% for ramipril and 17.0% for placebo, in 
non-symptomatic PAD (p = 0.53). In patients with clinical 
PAD, the incidence of myocardial infarction was 12.3% 
in the ramipril group and 16.1% in the placebo group, vs 
10.0% in the ramipril group vs 12.3% for placebo in non-
symptomatic PAD (p = 0.56). In patients with clinical PAD, 
the incidence of stroke was 6.2% for ramipril and 8.3% 
for placebo, vs 3.1% for ramipril and 4.7% for placebo 
in non-symptomatic PAD (p = 0.75). The cardiovascular 
mortality was 10.4% for ramipril and 13.6% for placebo, in 
clinical PAD, vs 5.5% for ramipril and 7.2% for placebo in 
non-symptomatic PAD (p = 0.79). All cause death was 16.7% 
for ramipril and 19.4% for placebo, in clinical PAD, and 9.5% 
for ramipril and 10.9% for placebo, in non-symptomatic PAD 
(p = 0.39). The incidence of revascularization was 25.2% 
for ramipril and 27.7% for placebo, in clinical PAD, and 
15.5% for ramipril and 17.7% for placebo in no symptomatic 
PAD (p = 0.78). The incidence diabetic complications 
was 22.1% for ramipril and 26.7% for placebo, in clinical 
PAD, and 15.0% for ramipril and 17.0% for placebo in no 
symptomatic PAD (p = 0.82). The incidence of hospitaliza-
tions for CHF was 5.0% for ramipril and 6.6% for placebo, 
in clinical PAD, and 2.8% for ramipril and 3.1% for placebo 
in non-symptomatic PAD (p = 0.22). In particular the relative 
beneﬁ  t was similar in patients subdivided by levels of ABI 
(RR of 0.83 with ABI   0.9, RR of 0.75 with ABI of 0.6–0.9 
and RR of 0.79 in those with ABI   0.6; p for heterogeneity 
was not signiﬁ  cant). Although not reaching the statistical 
signiﬁ  cance, ramipril reduced the risk of cardiovascular 
events in all groups of patients with clinical PAD and with 
subclinical PAD regardless of ABI.
Feringa et al (2006) sought to determine the effect of 
chronic treatment with cardiac medication, including statins, 
beta-blockers, aspirins, ACE-I, calcium channel blockers, 
diuretics, nitrates, coumarins, and digoxin on long-term 
mortality among patients with PAD (Feringa et al 2006). 
Statins, beta-blockers, aspirin and ACE-I are associated 
with a reduction in long-term mortality risk in patients with 
PAD that is independent of clinical risk factors. During a 
median follow-up of 8 years, 1067 patients (44%) died. After 
adjustment for risk factors and propensity scores ACE-I 
(HR 0.80, 95% CI 0.69–0.94) were signiﬁ  cantly associ-
ated with a reduced risk of long-term mortality. The use of 
cardiac medications as therapeutic and preventive agents 
in patients with PAD seems to be promising in reducing 
long-term mortality and could be incorporated among other 
management strategies, including walking exercise and risk 
factor modiﬁ  cation.
The HOPE Study has demonstrated that ramipril is 
beneﬁ  cial in a broad range of patients without evidence of 
left ventricular systolic dysfunction or heart failure who are at 
high risk for cardiovascular events (HOPE 2000). Treatment 
with ramipril reduced the rates of death from cardiovascular 
causes (6.1% compared with 8.1% in the placebo group; 
RR 0.74; p   0.001), myocardial infarction (9.9% vs 12.3%; 
RR 0.80; p   0.001), stroke (3.4% vs 4.9%; RR 0.68; 
p   0.001), death from any cause (10.4% vs 12.2%; RR 0.84; 
p = 0.005), revascularization procedures (16.0% vs 18.3 %; 
RR 0.85; p = 0.002), cardiac arrest (0.8% vs 1.3%; RR 0.63; 
p = 0.03), heart failure (9.0% vs 11.5%; RR 0.77; p   0.001), Vascular Health and Risk Management 2008:4(6) 1185
ACE-inhibitors and peripheral arterial disease
and complications related to diabetes (6.4% vs 7.6%; 
RR 0.84; p = 0.03).
The underlying rationale for the study was that the inhi-
bition of ACE would prevent events related to ischemia and 
atherosclerosis; the study therefore included a broad range 
of patients with any atherosclerosis manifestation: coronary 
artery disease (CAD), history of CVD or peripheral vascular 
disease, or diabetes and one cardiovascular risk factor; ramipril 
was beneﬁ  cial in all these subgroups. The beneﬁ  ts of ramipril 
were observed among patients who were already taking a 
number of effective treatments, such as aspirin, beta-blockers 
and lipid lowering agents, indicating that the inhibition of ACE 
offers an additional approach to the prevention of atherothrom-
botic complications. Only a small part of the beneﬁ  t could be 
attributed to a reduction in blood pressure, since the majority 
of patients did not have hypertension at baseline (according 
to conventional deﬁ  nitions) and the mean reduction in blood 
pressure with treatment was extremely small. However, in this 
study there was a 22% risk reduction in patients randomized 
to ramipril compared with placebo, which was independent 
of lowering of blood pressure. Based on this ﬁ  nding, the US 
Federal Drug Administration has now approved ramipril for 
its cardioprotective beneﬁ  ts in patients at high risk, including 
those with PAD. Thus, considering this like a drug class effect, 
the ACE-I would be recommended in patients with PAD.
The Study to Evaluate Carotid Ultrasound Changes in 
Patients Treated with Ramipril and Vitamin E (SECURE), 
a HOPE substudy, was a prospective, double-blind, 
332-patient factorial design trial that evaluated the effects of 
long-term treatment with the ACE-I ramipril and vitamin E 
on atherosclerosis progression in high-risk patients (Lonn 
et al 2001). The primary study analysis included 693 patients. 
There was an overall effect of ramipril, which reduced the 
annualized slope of the mean maximum IMT (intimal medial 
thickness) versus ramipril placebo (p = 0.033), and there was 
a strong trend for beneﬁ  t in the ramipril 10 mg/day group 
versus ramipril placebo (p = 0.028). There was a reduced 
atherosclerosis progression rate for ramipril overall versus 
ramipril placebo (p = 0.019) and for the ramipril 10 mg/day 
group versus ramipril placebo (p = 0.015). In the analysis 
of the 637 patients who completed carotid ultrasonography 
examinations, ramipril had a highly signiﬁ  cant effect on 
the single maximum IMT slope (p = 0.003 for the overall 
effect of ramipril versus placebo and p = 0.008 for ramipril 
10 mg/day versus placebo). This trial shows that long-term 
therapy with ramipril reduced atherosclerosis progression 
rates. This effect was noted in high-risk patients, the major-
ity of whom were already on effective therapy. Although the 
absolute differences in atherosclerosis progression rates 
between ramipril- and placebo-treated patients are small, 
the relative reduction in mean maximum IMT was 37% for 
ramipril 10 mg/day versus placebo, which is similar to the 
32% reduction in the risk of stroke in HOPE.
Ahimastos et al (2006) demonstrated that ramipril 
improves walking ability in patients with PAD. They 
examined the effect of 6-month ramipril therapy (10 mg of 
ramipril once daily) on walking distance and claudication, in 
a deﬁ  ned group of patients without diabetes and with clau-
dication due to infrainguinal PAD, by using a double-bind, 
randomized, placebo-controlled design. This study was 
conducted on 152 patients with PAD, of whom 40 were 
recruited and completed the trial. All patients had an ABI less 
than 0.9 at rest in at least 1 leg, had a history of intermittent 
claudication, which was stable for 6 months and had evidence 
of superﬁ  cial femoral artery stenosis or occlusion on duplex 
ultrasonography. All patients performed a treadmill exercise 
test to evaluate pain-free walking time and maximum walk-
ing time. The ramipril and placebo groups were similar in 
age, other cardiovascular risk factors, medication use and 
PAD severity, as evidenced by clinical symptoms (walking 
times), WIQ (Walking Impairment Questionnaire) scores 
and resting ABI. The study showed that ramipril increased 
ABI both at rest (p   0.001) and after exercise (p   0.001). 
At rest, this increase was due to reduction in brachial systolic 
blood pressure with ramipril treatment rather than an increase 
in limiting leg pressure. After exercise, both a reduction in 
brachial pressure (p   0.001) and an increase in limiting 
leg pressure (p   0.001) contributed to the increase in 
ABI. After adjuststment for the baseline pain-free walking 
time, mean pain-free walking time after ramipril treatment 
was 227 seconds (95% CI, 175–278 seconds; p   0.001) 
longer than that after placebo treatment. Similarly, maximum 
walking time improved by 451 seconds in the ramipril 
group (CI, 367 seconds to 536 seconds; p   0.001) but 
did not change in the placebo group. The magnitude of 
this effect is greater than that reported for convenctional 
medical therapies. Moreover, ramipril signiﬁ  cantly increased 
volume ﬂ  ow in the common femoral artery proximal to the 
site of stenosis in both the limiting leg (p   0.008) and the 
non-limiting leg (p   0.035). In this trial ramipril improved 
WIQ median distance score from 5% (range, 1%–39%) to 
21% (range, 12%–58%; p   0.001), speed score from 3% 
(range, 3% to 39%) to 18% (range, 8% to 50%; p   0.001), 
and stair-climbing score from 17% (range, 4%–80%) to 
67% (range, 38%–88%; p   0.001). In conclusion, ramipril 
therapy for 24 weeks increased both pain-free walking time Vascular Health and Risk Management 2008:4(6) 1186
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and maximum walking time by a clinically and statistically 
signiﬁ  cantly greater magnitude than current therapies.
Another study by Ahimastos et al (2008) supports the 
hypothesis that the beneﬁ  cial effects of ramipril on pain-free 
walking time observed in a PAD population are, at least partly, 
a consequence of reduced arterial stiffness. In this double-bind 
study, 40 patients with PAD were randomized to ramipril, 10 mg 
once daily or placebo for 24 weeks. In this study pain-free 
walking time was recorded during a standard treadmill test, 
indices of arterial stiffness were assessed globally by systemic 
arterial compliance and augmentation index and regionally via 
central pulse wave velocity. They found that ramipril increased 
maximum walking time by 243% and improved arterial stiffness 
parameters by between 17% and 64% (all p   0.001 compared 
with placebo). There were moderately strong correlations 
between the pre-/post-intervention change in maximum walking 
time and in indices of arterial stiffness (systemic arterial compli-
ance, r = 0.65, p   0.001; central pulse wave velocity, r = −0.57, 
p   0.001; augmentation index, r = –0.79, p   0.001; time to 
pressure augmentation, r = 0.52, p   0.001).
Conclusions
The imbalance between NO and Ang II activities associated 
with endothelial dysfunction and risk factors for CAD causes 
oxidative stress, which results from excessive production of 
oxygen-free radicals which counteracts the effects of NO, stimu-
lates expression of adhesion molecules and promotes adhesion 
of leukocytes to the endothelium. These actions cause an acute 
inﬂ  ammatory response, proliferation of smooth muscle cells 
and production of extracellular matrix, all of which contribute 
to the pathogenesis of cardiovascular disease (Griendling and 
Alexander 1997). The antiatherogenic ACE-I properties may 
be related both to the inhibition of tissue and circulating Ang II 
formation and to bradykinin potentiation, resulting in decreased 
proliferation and migration of smooth muscle cells, decreased 
accumulation and activation of inﬂ  ammatory cells, decreased 
oxidative stress, and increased endothelial NO formation, lead-
ing to improved endothelial function. The remarkable improve-
ment in the long-term prognosis of atherosclerotic patients with 
increased cardiovascular risk might be the clinical result of the 
contribution made by ACE inhibition in the vascular wall. On the 
basis of this ﬁ  nding, the latest ACC/AHA 2005 practice Guide-
lines for the Management of Patients With Peripheral Arterial 
Disease have suggested that the use of ACE-I is reasonable 
for symptomatic patients with lower extremity PAD in order 
to reduce the risk of adverse cardiovascular events (class IIa, 
Level of Evidence: B) and that ACE-I may be considered for 
patients with asymptomatic lower extremity PAD to reduce 
the risk of adverse cardiovascular events (class IIb, Level of 
Evidence: C) (Hirsch et al 2006). Yet, availability of newer neu-
rohormonal antagonists such as angiotensin receptor blockers, 
beta-blockers and aldosterone antagonists, lack of industry 
sponsorship for ACE-I, and aggressive promotion of statin have 
further slighted the role of this useful, safe and affective drug 
not only in the prevention of atherosclerosis vascular disease 
but also in improving walking ability in patients with PAD as 
consequence of reduced arterial stiffness. There is currently 
no evidence for the efﬁ  cacy of ACE-I in patients with asymp-
tomatic PAD, and, thus, the use of ACE-I medications to lower 
cardiovascular ischemic event rates in this population must be 
extrapolated from the data on symptomatic patients. The recent 
guidelines of the Trans-Atlantic Inter Society Consensus Docu-
ment on Management of PAD (TASC II) have recommended 
the control of hypertension in PAD patients, maintaining blood 
pressure values  140/90 mmHg or  130/80 mmHg if they 
have diabetes or renal insufﬁ  ciency (Grade A) (Norgren et al 
2007). The ACE-I should be considered as initial blood-pressure 
lowering drugs in PAD to reduce the risk of cardiovascular 
events (Grade B). Another recommendation regards the 
management of CAD in PAD patients. These patients with 
clinical evidence of CAD (angina, ischemic congestive heart 
failure) should be evaluated and managed according to current 
guidelines (Grade C). Patients with PAD considered for vascular 
surgery may undergo further risk stratiﬁ  cation and those found 
to be at very high risk managed according to current guidelines 
for coronary revascularization (Grade C).
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